Rigel Pharmaceuticals Inc (RIGL) Actualités

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease PR...

Form 8-K - Current report

Rigel Provides Business Update and 2025 Outlook

Rigel Provides Business Update and 2025 Outlook PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025...

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS PR Newswire SOUTH SAN FRANCISCO...

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif...